Blog
RSS FeedPosted by Michael Wonder on 20 Nov 2017
Bureaucracy and duplication: the reality of the PPRS
20 November 2017 - In the fourth in her series of five articles looking at the objectives of the PPRS, ...
Posted by Michael Wonder on 17 Nov 2017
Government launches scheme to deliver five “breakthrough technologies” a year
9 November 2017 - Is the promise of faster access to transformative medicine a good deal for patients or an ...
Posted by Michael Wonder on 16 Nov 2017
Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance
16 November 2017 - NICE has recommended palbociclib and ribociclib for routine funding after the companies lowered the prices and gave ...
Posted by Michael Wonder on 14 Nov 2017
NICE to play key role in UK drug fast-track scheme
14 November 2017 - NICE has been chosen to run the office that will decide which ground-breaking healthcare products will ...
Posted by Michael Wonder on 13 Nov 2017
NICE ‘no’ for short bowel syndrome drug Revestive
13 November 2017 - UK medicines cost-effectiveness watchdog NICE has published draft guidance today that does not recommend Revestive (teduglutide) ...
Posted by Michael Wonder on 12 Nov 2017
NHS England, Roche come to agreement on Perjeta
10 November 2017 - NHS England and Roche have agreed a confidential commercial agreement on the price of Perjeta for ...
Posted by Michael Wonder on 10 Nov 2017
NICE recommends Mavenclad (cladribine tablets) for highly active multiple sclerosis
9 November 2017 - First multiple sclerosis therapy to achieve positive NICE recommendation in the shortest possible timeframe. ...
Posted by Michael Wonder on 09 Nov 2017
NICE brings on board Sigma to boost med tech uptake
9 November 2017 - NICE is linking with user experience agency Sigma to develop a new system to improve the ...
Posted by Michael Wonder on 09 Nov 2017
NICE turns down Bayer’s Stivarga for liver cancer
8 November 2017 - Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced ...
Posted by Michael Wonder on 05 Nov 2017
NHS patients should have a choice of drug for wet age-related macular degeneration, despite pressure from pharma
1 November 2017 - Commissioners have to pay more than lip service to the obligation on us to find cost ...
Posted by Michael Wonder on 03 Nov 2017
ICR responds to Government report produced following Accelerated Access Review
3 November 2017 - The Institute of Cancer Research, London, today responds to the Government’s announcement of a new, fast-track ...
Posted by Michael Wonder on 03 Nov 2017
NHS patients to get faster access to 'breakthrough' medicines
3 November 2017 - Drug firms will be offered a fast-track route to get “breakthrough” medicines to NHS patients up ...
Posted by Michael Wonder on 02 Nov 2017
Final NICE nod for Sanofi’s Kevzara
2 November 2017 - The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as ...
Posted by Michael Wonder on 01 Nov 2017
NICE back Roche’s Tecentriq for CDF
1 November 2017 - The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the ...
Posted by Michael Wonder on 01 Nov 2017
Drug giants threaten NHS with legal action over cheaper drug that could save 84 million pounds a year
1 November 2017 - Using cheaper version of drug effective against blindness is preferable to cost-cutting measures such as rationing, say ...